TriSalus Life Sciences Inc美股招股说明书(2026-02-26版)

We are offering 9,756,100 shares of our common stock, par value $0.0001 per share (“Common Stock”), in this offering. Our Common Stock is listed on The Nasdaq Global Market under the symbol “TLSI.” On February 18, 2026, the last reported saleprice of our Common Stock on The Nasdaq Global Market was $4.64 per share. We are a “smaller reporting company” under the federal securities laws and, as such, have elected to comply with certain reducedreporting requirements for this prospectus and may elect to do so in future filings. Investing in our Common Stock involves a high degree of risk. See “Risk Factors” beginning on page S-4 of this prospectussupplement and in the documents incorporated by reference into this prospectus supplement before making your investmentdecision. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Anyrepresentation to the contrary is a criminal offense. (1)See “Underwriting” beginning on page S-9 for additional disclosure regarding the compensation to be received by the underwriter. We have granted a 30-day option to the underwriters to purchase up to 1,463,415 additional shares of Common Stock solely to coverover-allotments, if any. The underwriters expect to deliver the shares to purchasers on or about February 23, 2026. Sole Book-Runner Lake Street Prospectus supplement dated February 19, 2026 TABLE OF CONTENTS Prospectus Supplement ABOUT THIS PROSPECTUS SUPPLEMENTS-iiPROSPECTUS SUPPLEMENT SUMMARYS-1THE OFFERINGS-3RISK FACTORSS-4CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSS-5USE OF PROCEEDSS-6DILUTIONS-7DESCRIPTION OF THE SECURITIES WE ARE OFFERINGS-8UNDERWRITINGS-9LEGAL MATTERSS-11EXPERTSS-11WHERE YOU CAN FIND MORE INFORMATIONS-11INFORMATION INCORPORATED BY REFERENCES-12 Prospectus ABOUT THIS PROSPECTUS1PROSPECTUS SUMMARY2RISK FACTORS6CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS6USE OF PROCEEDS7DESCRIPTION OF CAPITAL STOCK7DESCRIPTION OF DEBT SECURITIES12DESCRIPTION OF WARRANTS19DESCRIPTION OF UNITS21LEGAL OWNERSHIP OF SECURITIES22PLAN OF DISTRIBUTION25LEGAL MATTERS28EXPERTS28WHERE YOU CAN FIND MORE INFORMATION28INCORPORATION OF DOCUMENTS BY REFERENCE29 ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying prospectus relate to an offering of our Common Stock. Before buying anyshares of the Common Stock that we are offering, we urge you to carefully read this prospectus supplement and the accompanyingprospectus, together with the information incorporated by reference as described under the headings “Where You Can Find MoreInformation” and “Information Incorporated by Reference” in this prospectus supplement as well as any free writing prospectus wehave provided for use in connection with this offering. These documents contain important information that you should consider whenmaking your investment decision. This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering ofCommon Stock and also adds to, updates and changes information contained in the accompanying prospectus and the documentsincorporated by reference. The second part is the accompanying prospectus, which provides more general information, some of whichmay not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined,together with the documents incorporated by reference herein and therein. To the extent the information contained in this prospectussupplement differs from or conflicts with the information contained in the accompanying prospectus or any document incorporated byreference having an earlier date, the information in this prospectus supplement will control. If any statement in one of these documentsis inconsistent with a statement in another document having a later date—for example, a document incorporated by reference into thisprospectus supplement and the accompanying prospectus—the statement in the document having the later date modifies or supersedesthe earlier statement. We have not, and the underwriter has not, authorized anyone to provide you with information different from thatwhich is contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writingprospectus that we may authorize for use in connection with this offering. Neither we, nor the underwriter, take any responsibility for,and can provide no assurance as to the reliability of, any other information that others may give you. When you make a decision aboutwhether to invest in our securities, you should not rely upon any information other than the information in this prospectus supplementor the accompanying prospectus, including any free writing prospectus that we have authorized for use in connection with thisoffering. You s